A double disk dermal device for administration of one or more active agents to the skin or mucosa of a host, in particular a patch is described including: a) active reservoir film layer; b) a backing overlay adjacent to the active reservoir film layer extending beyond the perimeter of the reservoir layer in all directions; c) second overlay backing layer with a coating of pressure sensitive adhesive which is adjacent to the first backing overlay extending beyond the perimeter of the first backing overlay in all directions; and d) a removable release liner. A method of making the device is also provided.

The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.

Dosing regimen for transdermal delivery of hormones comprising a variable treatment cycle and a variable rest interval.

A transdermal device (1) comprising at least one substrate (2) arranged to be applied against the dermal surface or the mucous membrane. The at least one active ingredient is grafted to the substrate (2) by at least one photolabile ligand, and at least one light source (11) operated by a control mechanism arranged to generate light pulses, of a predetermined wavelength, intended to break covalent bonds between the active ingredient and the ligand in order to release the active ingredient from the substrate (2). The substrate (2) comprises at least one porous matrix (6) with a three-dimensional structure comprising a plurality of pits (7) organized in a sponge-like fashion and constructed of a polymer chosen between chitin and chitosan, and the matrix (6) defines at least one three-dimensional tank (8). The active ingredient is contained and grafted by the ligand.

A solid dosage form comprises an inner core containing a cycloserine compound and an outer layer attached to the inner core. The dosage form can be enteric tablet or transdermal patch, suitable for treating a neuropsychiatric disorder or tuberculosis.

Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

Dosing regimen for transdermal delivery of hormones comprising a monthly treatment cycle with a fixed treatment interval and a variable rest interval.

Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

Disclosed is a vaccine composition for transdermal administration to induce cellular immunity, comprising an antigen, wherein Th1 cell ratio in a model animal for immunological evaluation that received the composition is 10% or more.

A method for the delivery of aggrecan precursors to the joint of a subject, comprising the steps of: a) applying a composition comprising one or more aggrecan precursors chosen from the list comprising hyaluronic acid, glucosamine sulfate and/or chondroitin sulfate to the skin of the subject on or near a joint, wherein the composition is applied between the skin and a flexible magnetic film.